SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) was the recipient of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 28,400 shares, a drop of 34.1% from the April 30th total of 43,100 shares. Based on an average daily trading volume, of 35,900 shares, the short-interest ratio is presently 0.8 days. Approximately 0.1% of the company's shares are short sold.

Wall Street Analyst Weigh In

Separately, BTIG Research set a $5.00 price target on shares of SOPHiA GENETICS in a report on Thursday, March 6th.

SOPHiA GENETICS Stock Up 3.8%

Shares of SOPH traded up $0.11 during mid-day trading on Friday, reaching $2.98. 44,689 shares of the stock traded hands, compared to its average volume of 54,357. The firm has a market cap of $198.73 million, a price-to-earnings ratio of -2.73 and a beta of 1.03. The stock has a fifty day simple moving average of $2.99 and a 200 day simple moving average of $3.27. SOPHiA GENETICS has a 12-month low of $2.58 and a 12-month high of $5.63. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). The firm had revenue of $17.78 million for the quarter, compared to analysts' expectations of $16.76 million. SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. Sell-side analysts expect that SOPHiA GENETICS will post -0.96 EPS for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds have recently made changes to their positions in SOPH. Federated Hermes Inc. raised its stake in shares of SOPHiA GENETICS by 40.5% during the fourth quarter. Federated Hermes Inc. now owns 100,000 shares of the company's stock valued at $312,000 after purchasing an additional 28,819 shares during the period. Dimensional Fund Advisors LP grew its position in shares of SOPHiA GENETICS by 23.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company's stock worth $68,000 after buying an additional 4,115 shares in the last quarter. Millennium Management LLC grew its position in shares of SOPHiA GENETICS by 6.5% during the fourth quarter. Millennium Management LLC now owns 698,634 shares of the company's stock worth $2,180,000 after buying an additional 42,689 shares in the last quarter. Silverberg Bernstein Capital Management LLC grew its position in shares of SOPHiA GENETICS by 54.4% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 34,675 shares of the company's stock worth $115,000 after buying an additional 12,211 shares in the last quarter. Finally, Bank Pictet & Cie Europe AG grew its position in shares of SOPHiA GENETICS by 14.4% during the first quarter. Bank Pictet & Cie Europe AG now owns 255,200 shares of the company's stock worth $847,000 after buying an additional 32,200 shares in the last quarter. Hedge funds and other institutional investors own 31.59% of the company's stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.